50% off Premium Yearly

NYSE:ELV
Out of favour in 2023. Healthcare is one of the areas where he expects the rotation to go, big opportunity. Stock's flat for last 2 years, but EPS is up 27%. 15x PE this year, 13.5x next year. Estimates of double-digit revenue growth and 15% annual earnings growth. The insurers, in particular, are ripe for a rebound. Yield is 1%.
(Analysts’ price target is $558.02)It is both a growth and value stock being a health insurer for corporations. It also provides management for the Federal Government through Medicare and Medicaid as well as its own networks. It is slowly becoming more vertically integrated. Being more on the defensive side it helps to balance his portfolio. Buy 21 Hold 4 Sell 0
Healthcare notoriously left out of most recent high-beta rally. Don't give up. Don't chase low-quality, high-beta companies just because they're going up for 6 weeks. Go with good quality companies, and you will be rewarded. He's sticking with it. Demographic tailwind, 6% FCF yield, expects $33 EPS in 2023 which is a 15x PE.
Elevance Health Inc is a American stock, trading under the symbol ELV (previously ELV-N on Stockchase) on the New York Stock Exchange (ELV). It is usually referred to as NYSE:ELV or ELV
In the last year, no analyst issued a Buy, Sell, or Hold rating on ELV (previously ELV-N on Stockchase) on Stockchase. Read the latest expert commentary for Elevance Health Inc.
Elevance Health Inc was recommended as a Top Pick by Gordon Reid on 2022-10-06. Read the latest stock experts ratings for Elevance Health Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Elevance Health Inc.
Elevance Health Inc is covered by Stockchase experts and is worth watching.
On 2026-06-18, Elevance Health Inc (ELV) stock closed at a price of $387.46.
Based on chart performance, this stock could be building a base. Waiting for new highs before purchasing. Could be promising.